NasdaqGS:NBIXBiotechs
Neurocrine Biosciences (NBIX) Showed New CRENESSITY Data, Is The Stock Still Cheap?
Neurocrine Biosciences (NBIX) is back in focus after presenting new CRENESSITY data at ENDO 2026, including first evidence in 11ß hydroxylase deficiency and two year cardiometabolic, bone, and quality of life findings.
See our latest analysis for Neurocrine Biosciences.
For investors, the ENDO 2026 data arrives at a time when momentum in Neurocrine Biosciences shares has been strong, with a 90 day share price return of 30.92% and a 1 year total shareholder return of 34.36% building on solid...